Back to search

Boston University

Early empiric antibiotic therapy discontinuation in pediatric patients with hematologic malignancy and febrile neutropenia

Abstract

dc:description.abstract

BACKGROUND: Infection is a major driver of morbidity and mortality in pediatric leukemia patients, who are highly susceptible to infections due to numerous risk factors associated with both the disease and its treatments. Febrile neutropenia, characterized by fever and an Absolute Neutrophil Count of ≤ 500 cells/mm³, is a common complication in this patient population. While fever is a key indicator of infection in neutropenic patients, its specificity is limited, often leading to excessive antibiotic use. This overuse contributes to the emergence of multi-drug resistant organisms (MDROs), posing a significant challenge to healthcare providers in balancing infection prevention and antibiotic stewardship. PROBLEM STATEMENT: Current guidelines for managing febrile neutropenia from the Children’s Oncology Group suggest empiric antibiotic therapy discontinuation in low-risk patients after bone marrow recovery, negative blood cultures at 48 hours, and 24 hours of apyrexia. However, there is ambiguity regarding risk stratification, bone marrow recovery, and whether it is essential to continue antibiotics until recovery. OBJECTIVE: The primary objective is to determine whether discontinuing empiric antibiotic therapy after 24 hours of apyrexia and 48 hours of negative blood cultures is non-inferior to continuation in pediatric leukemia patients with febrile neutropenia in terms of maintaining afebrile status and preventing serious infections. METHODS: This study is designed as a double-blind, placebo-controlled, randomized control trial conducted at a large medical center in Boston, MA. Eligible participants are pediatric patients with leukemia receiving treatment for febrile neutropenia. Patients will be randomized into two groups: one continuing empiric antibiotic therapy and the other receiving a saline placebo. Data will be collected on fever recurrence and infections. IMPLICATIONS: If successful, this study could lead to substantial changes in clinical guidelines: promoting shorter antibiotic courses, reducing the risk of side effects, and decreasing the selection pressure for Multi-Drug Resistant Organisms. The findings could also contribute to more consistent and effective care across institutions, reducing healthcare costs, and improving patient outcomes.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Physician Assistant Program
Grantor
Boston University
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Seils, Samantha
Advisors dc:contributor.advisor
  • Neri, Caitlin
  • Weinstein, John R.

Subjects

dc:subject × 8

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/51832

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Seils, Samantha. Early empiric antibiotic therapy discontinuation in pediatric patients with hematologic malignancy and febrile neutropenia. masters thesis, Boston University, 2024. https://hdl.handle.net/2144/51832